New test could prevent unneeded prostate cancer treatment

A new test from Genomic Health, the Oncotype DX Prostate Cancer Test, could reduce the number of men who undergo treatment for low-risk prostate cancer that would be better left untreated. The test rates the aggressiveness of a prostate biopsy based on an analysis of 17 genes and is more accurate than currently available tests, the developers say.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Paralegal, Legal-Regulatory
Confidential
Piscataway, NJ